Perfil
Matthew D.
Ronsheim is Chief Operating Officer at Xenon Pharmaceuticals, Inc. since 2024.
Formerly, Dr. Ronsheim was Executive Director & Head-Chemistry Manufacturing at Enanta Pharmaceuticals, Inc. from 2016 to 2019 and Chief Pharmaceutical Sciences Officer at Entasis Therapeutics Holdings, Inc. Education includes undergraduate studies at Southern Connecticut State University and a doctorate from the University of New Hampshire.
Cargos activos de Matthew Ronsheim
| Empresas | Cargo | Inicio |
|---|---|---|
| XENON PHARMACEUTICALS INC. | Director de Operaciones | 12/08/2024 |
Antiguos cargos conocidos de Matthew Ronsheim.
| Empresas | Cargo | Fin |
|---|---|---|
| ENANTA PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 01/08/2019 |
| ENTASIS THERAPEUTICS HOLDINGS INC. | Corporate Officer/Principal | - |
Formación de Matthew Ronsheim.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 5 |
|---|---|
Xenon Pharmaceuticals, Inc.
Xenon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovering, developing and delivering of therapeutics for neurological & psychiatric disorders | Health Technology |
Southern Connecticut State University
Southern Connecticut State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of New Hampshire
University of New Hampshire Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops small molecule drugs for the treatment of viral infections and liver diseases | Health Technology |
Entasis Therapeutics Holdings, Inc.
Entasis Therapeutics Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical biopharmaceutical company that engages in development of antibacterial products | Commercial Services |
- Bolsa de valores
- Insiders
- Matthew Ronsheim
















